Immuneering Corp - 8-K Filing
Immuneering Corporation reported updated data from its Phase 2a trial of atebimetinib in combination with modified Gemcitabine/nab-Paclitaxel for first-line pancreatic cancer, showing a median overall survival (mOS) of 17.3 months and an overall response rate (ORR) of 36% as of April 24, 2026. The company also outlined upcoming milestones including the start of a pivotal Phase 3 trial in mid-2026 and plans for trials combining atebimetinib with Libtayo® in non-small cell lung cancer. (Items: 8.01 Other Events)
Tickers: $IMRX